|
|
|
Volumn 13, Issue 4, 2015, Pages 232-234
|
|
The role of Sorafenib in hepatocellular carcinoma
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
LENVATINIB;
LIVER ENZYME;
PHOSPHATE;
SORAFENIB;
UREA;
YTTRIUM 90;
ANTINEOPLASTIC AGENT;
CARBANILAMIDE DERIVATIVE;
NICOTINAMIDE;
PROTEIN KINASE INHIBITOR;
CANCER SURVIVAL;
CHEMOEMBOLIZATION;
CHILD PUGH SCORE;
DIARRHEA;
DRUG DOSE REDUCTION;
DRUG EFFECT;
DRUG EFFICACY;
FATIGUE;
HAND FOOT SYNDROME;
HUMAN;
HYPERAMYLASEMIA;
HYPOPHOSPHATEMIA;
LIVER CELL CARCINOMA;
LIVER CIRRHOSIS;
LIVER FUNCTION;
MULTICENTER STUDY (TOPIC);
NOTE;
PHASE 3 CLINICAL TRIAL (TOPIC);
RANDOMIZED CONTROLLED TRIAL;
ANALOGS AND DERIVATIVES;
CARCINOMA, HEPATOCELLULAR;
CLINICAL TRIAL (TOPIC);
INTERVIEW;
LIVER NEOPLASMS;
PATHOLOGY;
RESEARCH;
TREATMENT FAILURE;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARCINOMA, HEPATOCELLULAR;
CLINICAL TRIALS AS TOPIC;
HUMANS;
HYPOPHOSPHATEMIA;
LIVER NEOPLASMS;
NIACINAMIDE;
PHENYLUREA COMPOUNDS;
PROTEIN KINASE INHIBITORS;
RESEARCH;
TREATMENT FAILURE;
TREATMENT OUTCOME;
|
|
EID: 84926677152
PISSN: 15430790
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (1)
|
|
References (5)
|
